BridgeBio Pharma Inc (NASDAQ:BBIO) price on current trading day, fall -1.44% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $34.49.
A look at the stock’s price movement, the level at last check in today’s session was $35.00, moving within a range at $34.29 and $35.195. The beta value (5-Year monthly) was 1.086. Turning to its 52-week performance, $41.04 and $21.62 were the 52-week high and 52-week low respectively. Overall, BBIO moved 25.48% over the past month.
BridgeBio Pharma Inc’s market cap currently stands at around $6.52 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 4.01M for the company’s revenue for the quarter, with a low and high estimate of 500k and 16.5M respectively. The average forecast suggests up to a 129.81% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 282.81M, representing a 2,940.00% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BBIO is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 9 recommend BBIO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BBIO’s current price about 17.99% and 26.23% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 72.41, while 7-day volatility ratio is 8.66% and 5.10% in the 30-day chart. Further, BridgeBio Pharma Inc (BBIO) has a beta value of 1.05, and an average true range (ATR) of 1.57. Analysts have given the company’s stock an average 52-week price target of $46, forecast between a low of $45 and high of $53. Looking at the price targets, the low is -30.47% off recent price level in today’s trading while to achieve the yearly target high, it has to move -53.67%. Nonetheless, investors will most likely welcome a -33.37% jump to $46 which is the analysts’ median price.
If we refocus on BridgeBio Pharma Inc (NASDAQ:BBIO), historical trading data shows that trading volumes averaged 3.19 over the past 10 days and 2.20 million over the past 3 months. The company’s latest data on shares outstanding shows there are 188.99 million shares.
The 21.81% of BridgeBio Pharma Inc’s shares are in the hands of company insiders while institutional holders own 75.83% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 19.3 million on 2024-12-31, giving us a short ratio of 11.24. The data shows that as of 2024-12-31 short interest in BridgeBio Pharma Inc (BBIO) stood at 1568.0 of shares outstanding, with shares short rising to 17.0 million registered in 2024-11-29. Current price change has pushed the stock 25.71% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BBIO stock continues to rise going into the next quarter.
